CSCI — COSCIENS Biopharma Share News
0.000.00%
Last trade - 00:00- CA$9.55m
- CA$4.91m
- $7.50m
Brief: Aeterna Zentaris Announces Notice Of Allowance For U.S. Patent Covering AEZS-150 For The Potential Treatment Of Chronic Hypoparathyroidism
Brief: Aeterna Zentaris Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule
Brief: Aeterna Zentaris Provides Business Outlook
Brief: Aeterna Zentaris Appoints Giuliano La Fratta As Chief Financial Officer
Brief: Aeterna Zentaris Provides Pipeline Program Updates
Brief: Aeterna Zentaris Announces Final Settlement Of Previously Disclosed Class-Action Lawsuit
Brief: Aeterna Zentaris - Preclinical Program To Qualify Macimorelin For Clinical Development As Potential Treatment Option For Amyotrophic Lateral Sclerosis
Brief: Aeterna Zentaris Commences Pivotal Phase 3 Detect-Trial For The Diagnosis Of Childhood-Onset Growth Hormone Deficiency
Brief: Aeterna Zentaris Reports Q1 Results
Aeterna Zentaris: Up on surge in quarterly revenue
Brief: Aeterna Zentaris Reports Fourth Quarter And Full Year 2020 Results
Brief: Aeterna Zentaris Files Prospectus By Selling Shareholders Of Up To 1.65 Million Co's Common Shares
Brief: Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Aeterna Zentaris Announces Exclusive License Agreement And Research Contract With Julius-Maximilians-University Wuerzburg For Development Of A Potential Oral Prophylactic Bacterial Vaccine Against Covid-19
Brief: Aeterna Zentaris Announces Initiation Of Its Preclinical Program For Treatment Of Primary Hypoparathyroidism
Brief: Aeterna Zentaris Increases Previously Announced Bought Deal Offering Of Common Shares To $29.7 Mln
U.S. STOCKS ON THE MOVE-Tetra, Atkore, AMC, Moleculin, Artelo, Durect, Aeterna
Aeterna Zentaris: Surges on progress in COVID-19 vaccine development
Brief: Aeterna Zentaris Announces Evaluation, Potential Development Of Oral Prophylactic Bacterial Vaccine Against COVID-19